Clonmel Healthcare introduce Oyavas®

Clonmel Healthcare are delighted to announce the introduction of Oyavas®, the new Bevacizumab biosimilar.

 

Oyavas® is an anti-VEGF monoclonal antibody, indicated for the treatment of the same 6 cancer types as the reference product*†1,2

 

  • Breast cancer
  • Cervical cancer
  • Colorectal cancer
  • Lung cancer
  • Ovarian cancer
  • Renal cell cancer

 

Oyavas® is confirmed to be biosimilar to the reference product*3, demonstrated according to EMA recommendations and guidelines.

 

SIMPLY CONVINCING – with similar efficacy, safety and quality to the reference product*3

 

Simply AFFORDABLE – with improved cost effectiveness compared to the reference product*4

 

Simply RELIABLE – with dedicated European production and comprehensive logistical support

 

Full prescribing information is available on request or alternatively please go to www.clonmel-health.ie.  Medicinal product subject to medical prescription.

Please contact Clonmel Healthcare on 01-6204000 or e-mail oyavas@clonmel-health.ie if you require any additional information.

 

 

Marketing authorisation number: EU/1/20/1510/001-002. Marketing authorisation holder: STADA Arzneimittel AG, Stadastrasse 2-18, 61118 Bad Vilbel, Germany. Date prepared: July 2021. 2021/ADV/OYA/077H.

 

*Avastin

† Not all treatment schedules within each cancer type are approved due to patent protection

  1. Oyavas SmPC (Apr. 2021).
  2. Avastin SmPC (Feb. 2021)
  3. Oyavas EPAR Public Assessment Report. Available at: https://www.ema.europa.eu/en/documents/assessment-report/oyavas-epar-public-assessment-report_en.pdf. Last accessed May 2021.
  4. Cost of Oyavas and reductions in price will vary depending on the market

Leave a Reply

Your email address will not be published.

Please Confirm

This website is only for the eyes of medical professionals. Are you a medical professional?